Wegovy for teens: injection, age, and the care-team questions the label actually answers

Wegovy injection is labeled for weight reduction in adolescents age 12 or older with obesity, alongside reduced-calorie diet and increased physical activity; Wegovy tablets are not established for pediatric use, and neither is the higher-dose injection for pediatric weight reduction. The label’s age and formulation distinction does not decide whether a particular teen should receive medication. The American Academy of Pediatrics places pharmacotherapy within family-centered, nonstigmatizing, ongoing pediatric care rather than a stand-alone retail weight-loss program.¹²

“Wegovy” is not one interchangeable pediatric option

The current prescribing information covers more than one Wegovy formulation. Its pediatric evidence and weight-reduction indication apply to the injection for adolescents 12 and older with obesity; whether an individual meets the relevant clinical and labeled criteria requires pediatric assessment. The label says safety and effectiveness of Wegovy tablets in pediatric patients have not been established. It separately says the higher-dose weekly injection has not been established for pediatric weight reduction. A website that lists only the brand name may conceal those distinctions.¹

This is not a dose-selection chart. A clinician must review the entire current label, including contraindications and warnings, and a family should receive a plan for follow-up and concerns. The Wegovy pill-versus-injection guide explains adult formulation differences; this page owns the narrower pediatric-label decision.¹

What a pediatric-quality consultation looks like

The AAP guideline recommends care through a medical-home approach that recognizes obesity’s biological, social, and structural contributors and avoids stigma. It advises offering adolescents 12 and older with obesity pharmacotherapy according to medication indications, risks, and benefits as an adjunct to health-behavior and lifestyle treatment. That is not a command to prescribe Wegovy to every teen meeting an age cutoff.²

A useful team can explain how it assesses the adolescent’s health and preferences, coordinates with the primary pediatric clinician, supports family participation appropriately, and follows physical and psychological well-being over time. Ask who would address a side effect between visits and how care remains respectful if medication is declined, paused, or not indicated. A consent packet and a recurring payment plan cannot substitute for that care structure.

The label contains pediatric safety information that deserves a direct discussion, including gallbladder events observed in the adolescent trial and a hypoglycemia warning when diabetes medicines are involved. Those facts are reasons for individualized review, not a prediction that an individual teen will experience an event. Do not use adult outcome claims or social-media anecdotes as a substitute for the pediatric evidence and the exact product label.¹

Questions families can take in

The adolescent’s participation matters alongside parental involvement. A teen may have a different view of symptoms, stigma, school routines, and what would count as a worthwhile outcome than an adult arranging the visit. Family-centered care should make space for those views without asking the teen to carry responsibility for a complex chronic condition alone. AAP’s guideline calls for a nonstigmatizing approach; a practice that relies on shame, a fixed appearance goal, or a before-and-after sales pitch is not reflecting that care model.²

Ask the clinic whether it can explain the pediatric evidence population in the Wegovy label. The supporting injection trial enrolled adolescents with obesity; it is not evidence for a cosmetic “last few pounds” use in a teen, nor for the tablet. That distinction helps families avoid applying an adult marketing claim to a child simply because the active molecule is semaglutide.¹

Ask: “Which Wegovy formulation are you proposing, and where does its label address this adolescent’s age and indication? Who is the pediatric clinician responsible for evaluation and follow-up? How are medical and psychological concerns assessed without making weight the child’s whole identity? What happens if the family chooses another evidence-based care path?”

The medical weight-management hub can help identify consultation options. Before booking, confirm that the practice actually evaluates adolescents and can coordinate pediatric care; a general adult service listing does not establish that capability.